Olmesartán/Amlodipino/Hidroclorotiazida Pensa (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan/Amlodipine/HCTZ acts on multiple pathways to lower elevated blood pressure in hypertensive patients.

• Essential hypertension: provides consistent reduction of systolic and diastolic pressure in adults.
• Uncontrolled hypertension: adds therapeutic effect when monotherapy does not achieve target levels.
• Hypertension with fluid retention: combines a diuretic to counteract edema associated with calcium‑channel blockade.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. Hydrochlorothiazide reduces sodium and chloride reabsorption in the distal convoluted tubule, promoting diuresis and decreasing plasma volume. The three actions synergistically lower systemic vascular resistance and blood volume, resulting in sustained blood‑pressure control.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Peripheral edema: swelling of ankles due to amlodipine’s vasodilatory effect.
• Flushing: temporary warmth and redness of the skin.
• Fatigue: general tiredness during early treatment.
• Increased urination: diuretic‑related fluid loss.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Electrolyte imbalance: abnormal potassium or sodium levels, potentially causing cardiac arrhythmia.
• Acute kidney injury: reduced renal function, especially in volume‑depleted patients.
• Angioedema: rapid swelling of face, lips, or airway requiring emergency care.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Patients should be monitored closely for safety and efficacy when initiating therapy.

• Monitor blood pressure: adjust dose to achieve target levels.
• Assess renal function: evaluate creatinine and eGFR before and during treatment.
• Check electrolytes: especially potassium and sodium concentrations.
• Avoid in pregnancy: contraindicated due to risk of fetal toxicity.
• Caution with hepatic impairment: dose may need adjustment.
• Store at ambient temperature: keep in original container, protect from moisture.

Olmesartan/Amlodipine/HCTZ may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Potassium‑sparing diuretics: increase risk of hyperkalemia.
• ACE inhibitors or ARBs with aliskiren in diabetic patients: heightened adverse‑effect profile.
• Lithium: elevated lithium levels and toxicity.
• NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering effect.
• Other thiazide‑type diuretics: potential electrolyte disturbances.
• Strong CYP3A4 inhibitors (e.g., ketoconazole): raise amlodipine plasma concentrations.